Bank of America Corp DE Increases Position in Nkarta, Inc. (NASDAQ:NKTX)

Bank of America Corp DE raised its holdings in Nkarta, Inc. (NASDAQ:NKTX - Free Report) by 110.1% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 380,444 shares of the company's stock after purchasing an additional 199,345 shares during the quarter. Bank of America Corp DE owned 0.54% of Nkarta worth $947,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. JPMorgan Chase & Co. increased its position in shares of Nkarta by 138.7% during the 4th quarter. JPMorgan Chase & Co. now owns 2,537,922 shares of the company's stock worth $6,319,000 after purchasing an additional 1,474,560 shares during the last quarter. Wasatch Advisors LP increased its position in shares of Nkarta by 37.4% during the fourth quarter. Wasatch Advisors LP now owns 2,520,909 shares of the company's stock valued at $6,277,000 after acquiring an additional 686,229 shares during the last quarter. Alyeska Investment Group L.P. raised its stake in shares of Nkarta by 23.0% in the 4th quarter. Alyeska Investment Group L.P. now owns 1,334,696 shares of the company's stock valued at $3,323,000 after acquiring an additional 250,000 shares during the period. Geode Capital Management LLC raised its stake in shares of Nkarta by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 1,181,357 shares of the company's stock valued at $2,942,000 after acquiring an additional 10,331 shares during the period. Finally, Affinity Asset Advisors LLC lifted its holdings in shares of Nkarta by 23.1% in the 4th quarter. Affinity Asset Advisors LLC now owns 800,000 shares of the company's stock worth $1,992,000 after acquiring an additional 150,000 shares during the last quarter. Institutional investors and hedge funds own 80.54% of the company's stock.

Nkarta Stock Performance

Shares of Nkarta stock traded down $0.03 during trading hours on Monday, reaching $1.87. 539,876 shares of the company were exchanged, compared to its average volume of 1,062,431. The firm has a market cap of $132.69 million, a PE ratio of -0.99 and a beta of 0.72. Nkarta, Inc. has a 1 year low of $1.31 and a 1 year high of $8.23. The stock's fifty day moving average is $1.82 and its 200 day moving average is $2.07.

Nkarta (NASDAQ:NKTX - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.43) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.01. Research analysts expect that Nkarta, Inc. will post -1.7 earnings per share for the current year.

Analysts Set New Price Targets

NKTX has been the subject of a number of research analyst reports. Needham & Company LLC lowered their price objective on shares of Nkarta from $11.00 to $10.00 and set a "buy" rating for the company in a research report on Thursday, May 15th. William Blair reiterated a "market perform" rating on shares of Nkarta in a report on Thursday, May 15th. HC Wainwright reissued a "buy" rating and set a $18.00 target price on shares of Nkarta in a research note on Thursday, March 27th. Finally, Stifel Nicolaus lowered their target price on Nkarta from $15.00 to $14.00 and set a "buy" rating for the company in a report on Thursday, March 27th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Nkarta has a consensus rating of "Buy" and a consensus target price of $14.67.

Nkarta Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.